Bank of America: Storage cycle bids farewell to “J-shaped” growth, but fundamental upside remains vast; chip shortage may persist until 2027
智通财经2026/10/05 03:26According to Jinse Finance, Bank of America recently released a research report stating that as the fourth quarter of 2026 approaches, the storage cycle will gradually exit the previous J-shaped growth stage and enter a new phase of development. This is consistent with Micron Technology's (MU.US) recently announced performance and latest guidance: the company's sales in the fourth quarter of fiscal year 2026 are expected to increase by 31% quarter-on-quarter, lower than the 74% in the third quarter; the company expects sales in the first quarter of fiscal year 2027 to grow by only 13.5% quarter-on-quarter.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US 10-year and 30-year Treasury yields rise
U.S. Treasury yields have risen, with the 10-year Treasury yield increasing by 2.34 basis points to 5.3%, and the 30-year Treasury yield rising by 2.64 basis points to 5.656%.
S&P downgrades Nike's credit rating to A with a negative outlook
S&P Global Ratings has downgraded Nike (NKE.US) credit rating to "A" with a negative outlook.
S&P: Nike’s business transformation period will be prolonged and its cash flow is expected to drop significantly
S&P Global Ratings: Nike (NKE.US) is undergoing a prolonged business transformation, and its cash flow is expected to decline significantly.
BUZZ-Leerink downgrades Bristol-Myers Squibb rating, citing risks in the R&D pipeline
October 5th - ** Bristol-Myers Squibb (BMY.N) shares fell 1.9% to $60 in pre-market trading ** ** Leerink Partners downgraded the pharmaceutical company's stock rating from “Outperform” to “Market Perform” and lowered its target price from $73 to $59 ** ** As of the previous trading session's close, BMY had risen 13.4% year to date; the new target price implies about 3.5% downside ** ** The brokerage highlighted uncertainty around three key projects for BMY and noted approaching patent expirations ** ** Leerink warned that the experimental pulmonary drug admilparant may disappoint in terms of efficacy and safety, citing possible liver issues and low blood pressure; it cut 2032 sales forecast by 38% ** ** They questioned whether experimental anticoagulant milvexian can rival Bristol-Myers Squibb’s Eliquis in preventing strokes in patients with atrial fibrillation, and lowered 2032 sales forecast by 25% ** ** Even if the antipsychotic drug Cobenfy is approved for treating Alzheimer’s-related psychosis, demand may still be limited by the availability of lower-priced generic antipsychotics ** ** EPS forecast for 2032 was cut by 11% to $4.96 (For non-native speakers’ convenience, Reuters automatically translates articles into multiple languages; Reuters makes no guarantee of accuracy due to possible automated translation errors or lack of context, and accepts no liability for any damages caused by use of the machine translation. The machine-translated text is provided solely for reader convenience.)
Crypto prices
More
